Lantheus Holdings Inc
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceut… Read more
Lantheus Holdings Inc (LNTH) - Net Assets
Latest net assets as of December 2025: $1.09 Billion USD
Based on the latest financial reports, Lantheus Holdings Inc (LNTH) has net assets worth $1.09 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.23 Billion) and total liabilities ($1.14 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.09 Billion |
| % of Total Assets | 48.93% |
| Annual Growth Rate | N/A |
| 5-Year Change | 134.65% |
| 10-Year Change | N/A |
| Growth Volatility | 117.78 |
Lantheus Holdings Inc - Net Assets Trend (2012–2025)
This chart illustrates how Lantheus Holdings Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Lantheus Holdings Inc (2012–2025)
The table below shows the annual net assets of Lantheus Holdings Inc from 2012 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.09 Billion | +0.16% |
| 2024-12-31 | $1.09 Billion | +33.35% |
| 2023-12-31 | $815.89 Million | +82.47% |
| 2022-12-31 | $447.15 Million | -3.72% |
| 2021-12-31 | $464.44 Million | -9.68% |
| 2020-12-31 | $514.21 Million | +348.69% |
| 2019-12-31 | $114.60 Million | +61.41% |
| 2018-12-31 | $71.00 Million | +204.85% |
| 2017-12-31 | $23.29 Million | +121.87% |
| 2016-12-31 | $-106.52 Million | +42.51% |
| 2015-12-31 | $-185.29 Million | +22.56% |
| 2014-12-31 | $-239.27 Million | -1.59% |
| 2013-12-31 | $-235.52 Million | -36.05% |
| 2012-12-31 | $-173.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lantheus Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 95880200000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $679.50 Million | 62.35% |
| Common Stock | $718.00K | 0.07% |
| Other Comprehensive Income | $-1.31 Million | -0.12% |
| Other Components | $410.88 Million | 37.70% |
| Total Equity | $1.09 Billion | 100.00% |
Lantheus Holdings Inc Competitors by Market Cap
The table below lists competitors of Lantheus Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Founder Securities Co Ltd
SHG:601901
|
$4.54 Billion |
|
United Integrated Services Co Ltd
TW:2404
|
$4.54 Billion |
|
Bezeq The Israel Telecommunication Corp. Ltd
PINK:BZQIF
|
$4.54 Billion |
|
Jfrog Ltd
NASDAQ:FROG
|
$4.54 Billion |
|
Indra A
MC:IDR
|
$4.54 Billion |
|
China Satellite Communications Co Ltd
SHG:601698
|
$4.53 Billion |
|
Macy’s Inc
NYSE:M
|
$4.53 Billion |
|
Turkcell Iletisim Hizmetleri AS
NYSE:TKC
|
$4.53 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lantheus Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,088,011,000 to 1,089,797,000, a change of 1,786,000 (0.2%).
- Net income of 233,559,000 contributed positively to equity growth.
- Share repurchases of 300,017,000 reduced equity.
- New share issuances of 3,727,000 increased equity.
- Other comprehensive income increased equity by 308,000.
- Other factors increased equity by 64,209,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $233.56 Million | +21.43% |
| Share Repurchases | $300.02 Million | -27.53% |
| Share Issuances | $3.73 Million | +0.34% |
| Other Comprehensive Income | $308.00K | +0.03% |
| Other Changes | $64.21 Million | +5.89% |
| Total Change | $- | 0.16% |
Book Value vs Market Value Analysis
This analysis compares Lantheus Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.93x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-9.57 | $78.50 | x |
| 2013-12-31 | $-12.80 | $78.50 | x |
| 2014-12-31 | $-13.23 | $78.50 | x |
| 2015-12-31 | $-7.58 | $78.50 | x |
| 2016-12-31 | $-3.26 | $78.50 | x |
| 2017-12-31 | $0.60 | $78.50 | x |
| 2018-12-31 | $1.80 | $78.50 | x |
| 2019-12-31 | $2.86 | $78.50 | x |
| 2020-12-31 | $9.50 | $78.50 | x |
| 2021-12-31 | $6.88 | $78.50 | x |
| 2022-12-31 | $6.33 | $78.50 | x |
| 2023-12-31 | $11.62 | $78.50 | x |
| 2024-12-31 | $15.18 | $78.50 | x |
| 2025-12-31 | $15.92 | $78.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lantheus Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 21.43%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.15%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 2.04x
- Recent ROE (21.43%) is below the historical average (49.50%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | -14.58% | 0.89x | 0.00x | $-24.69 Million |
| 2013 | 0.00% | -21.70% | 1.09x | 0.00x | $-38.00 Million |
| 2014 | 0.00% | -1.18% | 1.21x | 0.00x | $20.37 Million |
| 2015 | 0.00% | -5.02% | 1.21x | 0.00x | $3.78 Million |
| 2016 | 0.00% | 8.87% | 1.18x | 0.00x | $37.41 Million |
| 2017 | 529.75% | 37.23% | 0.86x | 16.48x | $121.06 Million |
| 2018 | 57.07% | 11.80% | 0.78x | 6.19x | $33.42 Million |
| 2019 | 27.63% | 9.12% | 0.86x | 3.54x | $20.21 Million |
| 2020 | -2.62% | -3.97% | 0.39x | 1.69x | $-64.89 Million |
| 2021 | -15.35% | -16.76% | 0.49x | 1.86x | $-117.72 Million |
| 2022 | 6.28% | 3.00% | 0.71x | 2.95x | $-16.65 Million |
| 2023 | 40.04% | 25.20% | 0.79x | 2.02x | $245.07 Million |
| 2024 | 28.72% | 20.37% | 0.77x | 1.82x | $203.64 Million |
| 2025 | 21.43% | 15.15% | 0.69x | 2.04x | $124.58 Million |
Industry Comparison
This section compares Lantheus Holdings Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $580,491,146
- Average return on equity (ROE) among peers: -45.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lantheus Holdings Inc (LNTH) | $1.09 Billion | 0.00% | 1.04x | $4.54 Billion |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $14.78 Million | -64.19% | 0.99x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $-241.47K | 0.00% | 0.00x | $603.58K |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -329.21% | 0.78x | $194.64 Million |
| Acreage Holdings Inc (ACRDF) | $494.79 Million | -30.37% | 0.40x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $37.06 Million | 39.05% | 0.16x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $32.70 Million | -18.88% | 0.16x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $21.19 Million | 12.93% | 1.96x | $1.84 |
| Adcock Ingram Holdings Limited (AIHLF) | $4.54 Billion | 14.90% | 0.58x | $85.61 Million |